Full Text View
Tabular View
No Study Results Posted
Related Studies
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), August 2009
First Received: October 18, 2008   Last Updated: November 25, 2009   History of Changes
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00776412
  Purpose

This study will collect information about markers of inflammation, blood clotting and blood vessel function in HIV-infected adults and healthy volunteers. Biomarkers are biological indicators that have been associated with disease. Certain markers of inflammation, blood clotting, and blood vessel function have been associated with risk of cardiovascular disease, stroke and death. One marker, called D-dimer, is a breakdown product of blood clots that has been associated with serious medical conditions, including deep vein thrombosis (formation of a blood clot in a vein deep in the body) and pulmonary embolism (blockage in the pulmonary artery that occurs when a blood clot from a vein breaks away, travels to the pulmonary artery and lodges there). High D-dimer levels have also been associated with cardiovascular disease and stroke risk. In a recent study of HIV-infected patients, higher D-dimer levels were strongly correlated with risk of death from any cause. The significance of changes in D-dimer and other biomarkers in HIV-infected adults is not well understood. This study will further explore D-dimer and other biomarkers to try to better understand the relationships between them and HIV infection.

Healthy volunteers and HIV-infected adults 18 years of age or older may be eligible for this study. Two visits are involved, as follows:

Visit 1 (screening visit to determine eligibility)

  • Medical history and physical examination.
  • Blood tests for HIV infection, blood counts, liver and kidney function.
  • Pregnancy test for women who can become pregnant.

Visit 2

  • Blood tests for hepatitis B and C
  • Blood tests for markers of inflammation and blood clotting.
  • Blood test for genetic changes that influence blood clotting.

In some cases, visits 1 and 2 may be combined.

Optional additional visits (up to 8 visits over 3 years)

  • Additional blood draws for investigation of specific clinical or laboratory findings may be requested.

Condition
Cardiovascular Disease
HIV Infections

Study Type: Observational
Study Design: Prospective
Official Title: Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 250
Study Start Date: October 2008
Detailed Description:

D-dimer, a fibrin degradation product generated as a result of plasmin mediated clot dissolution processes, is an indicator of recent clot formation and subsequent fibrinolysis. Analysis of D-dimer concentration is employed in the diagnosis of deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. More recently, D-dimer levels have been correlated with atherosclerotic cardiovascular disease. In a recent case-control study of biomarkers for cardiovascular disease in human immunodeficiency virus (HIV)-infected adults, baseline D-dimer levels strongly correlated with all-cause mortality. Notably, the association between baseline D-dimer levels and death due to cardiovascular disease was less significant.

At present, the pathophysiology underlying the association of elevated D-dimer concentrations with mortality in HIV is not understood. This study seeks to identify possible mechanisms underlying D-dimer elevations in HIV-infected adults by investigating a number of pathways that may be associated with the elevations using biomarkers of inflammation, hemostasis, thrombosis, platelet function, lipid metabolism, and additional indicators of endothelial function. Further elucidation of plausible pathways contributing to D-dimer elevation could, ultimately, lead to trials of risk-reducing interventions for patients with an elevated D-dimer level.

This study, an exploratory, cross-sectional study of up to 200 subjects, seeks to prospectively collect data on D-dimer and related biomarkers in HIV-infected adults. Initially, the study will recruit HIV-infected adults with HIV viremia who are not taking antiretroviral therapy and compare their clinical histories and biomarker findings with those from (1) a group of HIV-infected adults with controlled HIV viremia who are receiving antiretroviral therapy, and with those from (2) a control group of HIV-negative healthy subjects.

The study requires 2 visits for screening, history and physical examination, and phlebotomy. A wide array of research assays investigating different aspects of inflammation, coagulation, and endothelial function will be completed. Samples will be stored for future investigation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:
  • Age greater than or equal to 18 years
  • Ability to understand and provide informed consent
  • Adequate venous access
  • Adequate blood counts (hemoglobin greater than or equal to 9.0 g/dL, platelets greater than or equal to 50,000 cells/mm(3))
  • Willing and able to comply with study requirements and procedures including storage of blood samples for use in future studies of HIV, AIDS, immune function, inflammation, coagulation, and atherosclerosis
  • Negative serum pregnancy test for females of child-bearing potential (female subjects who have medical documentation of hysterectomy and/or bilateral oophorectomy do not need to undergo pregnancy testing)

For HIV-negative subjects:

- No known history of HIV infection. At enrollment, HIV antibody testing will be performed to confirm negative HIV-1 antibody status.

For HIV-positive subjects:

  • Established HIV diagnosis (previous documentation of HIV-1 infection in the subject's medical record; for subjects without such confirmation, positive ELISA testing confirmed by Western Blot or plasma HIV viral load greater than 10,000 copies/mL)
  • Must be under the care of a physician for HIV and general medical issues.

EXCLUSION CRITERIA:

  • Pregnant or breast-feeding
  • Known bleeding or clotting disorder including history of deep vein thrombosis, pulmonary embolism, or hemophilia
  • Current use of warfarin, low molecular weight heparin, clopidogrel or experimental platelet aggregation inhibitor
  • Concurrent malignancy requiring cytotoxic chemotherapy or radiation therapy
  • Substance abuse or severe psychiatric disorder that would interfere with adherence to protocol requirements
  • Any serious medical condition for which the principal investigator feels participation may be contraindicated
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00776412

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, District of Columbia
Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Additional Information:
Publications:
Study ID Numbers: 090013, 09-I-0013
Study First Received: October 18, 2008
Last Updated: November 25, 2009
ClinicalTrials.gov Identifier: NCT00776412     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Cardiovascular Disease
D-dimer
Antiretroviral
Mortality
HIV Positive
HIV Negative
Healthy Volunteer
HV

Additional relevant MeSH terms:
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Immune System Diseases
Acquired Immunodeficiency Syndrome
Infection
Immunologic Deficiency Syndromes
Inflammation
Virus Diseases
Pathologic Processes
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections
Cardiovascular Diseases
Retroviridae Infections

ClinicalTrials.gov processed this record on February 08, 2010